La mia nuova descrizione qui!
Price of a print issue €25.00
INTRODUCTION: Fulminant hepatic failure is the end result of many different acute damage to the liver. In the present
study we compared the clinical to the experimental experience and we postulated the usage of Vascular Endothelial
Growth Factor in the clinical arena as a potential treatment in alternative to liver transplantation.
MATERIALS AND METHODS: Twelve patient diagnosed with fulminat hepatic failure have been enclosed in the present
study. Each patient underwent trans-jugular liver biopsy in order to assess the degree of liver necrosis as well as the following
biochemical investigation: AST, ALT, Total Bilirubin, _gt, alkaline phosphatase, prothrombin time.
RESULTS: Twenty-five percent of those patients required support in the Intensive Care Unit without need for transplantation.
Forty-one percent of those patients underwent liver transplantation, and 36% of them died before the liver become
available. These results were compared with an experiment, previously performed by our group, where 260 rats were
poisoned with CCl4 and subsequently treated with Vascula Endothelial Growth Factor (VEGF).
CONCLUSION: The rate of the hepatic regeneration has been found to be critical in the prognosis of patients diagnosed
with fulminant hepatic failure.